title: Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial.
abstract: BACKGROUND
  In the CALYPSO trial, carboplatin-pegylated liposomal doxorubicin (CD) demonstrated superior therapeutic index versus carboplatin-paclitaxel (CP) in patients with recurrent ovarian cancer. This paper reports the health-related quality of life (HRQoL) findings.
  
  
  METHODS
  HRQoL was measured with the EORTC QoL-QC30 questionnaire and OV28 ovarian cancer module. Mean change scores from baseline in HRQoL subscales (five functional scales and global health status) in each arm and the proportion of patients improved or worsened were calculated every 3 months until 12 months.
  
  
  RESULTS
  Compliance was 90% at baseline and 76%, 64%, 57% at 3, 6, and 9 months, respectively. Baseline HRQoL showed already impaired global scores (mean 62/100) and considerable symptom burden (90% of patients reporting nonzero scores). Global QoL and abdominal symptom scores improved over time in both arms; at 6 months, 36% of patients met criteria for improved symptoms. Treatment with CD resulted in less peripheral neuropathy (9.8 versus 24.2), fewer other chemotherapy side-effects (9.5 versus 16.2), and less impact on body image (3.8 versus 10.4) versus CP (all P<0.02) at 6 months.
  
  
  CONCLUSIONS
  These patient-reported outcomes confirm the overall lower toxicity of CD versus CP. The improved disease-related outcomes achieved with CD were not at the expense of QoL.
authors.affiliation: NCIC Clinical Trials Group; Department of Medical Oncology, Queen's University, Kingston, Canada. Electronic address: michael.brundage@krcc.on.ca.
authors.forename: M
authors.initials: M
authors.lastname: Brundage
authors.affiliation: Department of Medical Oncology, AGO, Düsseldorf, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Gropp
authors.affiliation: Department of Medical Oncology, GINECO, Saint-Cloud, France.
authors.forename: F
authors.initials: F
authors.lastname: Mefti
authors.affiliation: Department of Medical Oncology, National Health and Medical Research Council Clinical Trials Centre, Sydney, Australia.
authors.forename: K
authors.initials: K
authors.lastname: Mann
authors.affiliation: Department of Oncology, Aalborg Hospital, Aalborg, Denmark.
authors.forename: B
authors.initials: B
authors.lastname: Lund
authors.affiliation: National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia.
authors.forename: V
authors.initials: V
authors.lastname: Gebski
authors.affiliation: Department of Gynecology, Arbeitsgemeinschaft Gynaekologische Onkologie-Austria, Ried, Austria.
authors.forename: G
authors.initials: G
authors.lastname: Wolfram
authors.affiliation: Beatson Oncology Centre, Gartnavel General Hospital, Glasgow, UK.
authors.forename: N
authors.initials: N
authors.lastname: Reed
authors.affiliation: Multicenter Italian Trials in Ovarian Cancer (MITO), Napoli.
authors.forename: S
authors.initials: S
authors.lastname: Pignata
authors.affiliation: Academic Division of Gynecologic Oncology, Mauriziano Hospital, Torino, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Ferrero
authors.affiliation: NHMRC Clinical Trials Centre, Sydney, Australia.
authors.forename: C
authors.initials: C
authors.lastname: Brown
authors.affiliation: NCIC Clinical Trials Group; Department of Medical Oncology, Queen's University, Kingston, Canada.
authors.forename: E
authors.initials: E
authors.lastname: Eisenhauer
authors.affiliation: Department of Oncology, Hôpital Hôtel-Dieu, Paris, France.
authors.forename: E
authors.initials: E
authors.lastname: Pujade-Lauraine
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D055118:Medication Adherence; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects; D011788:Quality of Life
chemical_list: C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin; D016190:Carboplatin; D017239:Paclitaxel